Product logins

Find logins to all Clarivate products below.


Unipolar Depression | Access and Reimbursement | Major Depressive Disorder | US | 2017

Numerous drugs across multiple drug classes are available for the treatment of MDD. Yet current therapies are not sufficiently effective in all patients, and those patients with TRD have become the target of drug development. Furthermore, the treatment armamentarium is growing increasingly genericized, which has improved patient access to antidepressants as well as eased restrictions on off-label adjunctive use of atypical antipsychotics. At the same time, the expanding generics presence has given payers greater leverage to control drug-treatment costs in MDD. Understanding the current and expected influence of clinical metrics and value for dollar on market access and medical practice are key for developers of new therapies for MDD.

Questions Answered:

  • What factors influence physician prescribing of select therapies for MDD? Which therapies are succeeding and which are stumbling based on these factors?
  • In this mature and highly genericized treatment landscape, what actions can marketers of therapies used to treat MDD employ to attain successful market access and thus overall sales?
  • How are MCOs performing value assessments for MDD therapies, and what are the preferred pharmacoeconomic models?
  • To which of their MDD patients do physicians anticipate prescribing the emerging therapies ALKS-5461 (Alkermes), esketamine (Janssen), and rapastinel (Allergan)? How do payers expect to reimburse these therapies?

Product Description:

Access & Reimbursement: Provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.

Related Market Assessment Reports

Report
Beta Thalassemia – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Beta thalassemia (BT) is a rare genetic disorder characterized by the reduced production of hemoglobin. BT minor is caused by a mutation in one hemoglobin beta (HBB) gene, and transfusion-dependent…
Report
Multiple Sclerosis – Unmet Need – Unmet Need – Multiple Sclerosis: Nonrelapsing Secondary-Progressive Multiple Sclerosis (US/EU)
No treatments are approved for nonrelapsing secondary-progressive multiple sclerosis (nrSP-MS), an MS disease course in which physical disability accumulates in the absence of superimposed relapses…
Report
Myasthenia Gravis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myasthenia Gravis (US)
Myasthenia gravis (MG) is a rare neuromuscular disorder caused by specific autoantibodies at the neuromuscular junction; in most patients, these autoantibodies target acetylcholine receptors. MG is…
Report
Osteoarthritic Pain – Current Treatment – Treatment Algorithms: Claims Data Analysis – Osteoarthritic Pain (US)
Osteoarthritic (OA) pain affects more than 30 million people in the United States, and the aging population and rising obesity rates are expected to drive further increases. Current treatments,…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Heart Failure (US)
Chronic heart failure (CHF) manifests as impaired cardiac function and consequent failure to maintain sufficient blood flow throughout the body to meet its metabolic demands. The CHF therapy market…